Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial

Katherine R Tuttle¹

Affiliations

Affiliation

¹ Providence Medical Research Center, Providence Health Care, Spokane, WA, USA; Nephrology Division, University of Washington School of Medicine, Seattle, WA 99204, USA. Electronic address: katherine.tuttle@uw.edu.

PMID: 34619107
DOI: 10.1016/S2213-8587(21)00265-5

Comment

Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial

Katherine R Tuttle. Lancet Diabetes Endocrinol. 2021 Nov.

. 2021 Nov;9(11):727-728.

doi: 10.1016/S2213-8587(21)00265-5. Epub 2021 Oct 4.

Author

Katherine R Tuttle¹

Affiliation

¹ Providence Medical Research Center, Providence Health Care, Spokane, WA, USA; Nephrology Division, University of Washington School of Medicine, Seattle, WA 99204, USA. Electronic address: katherine.tuttle@uw.edu.

PMID: 34619107
DOI: 10.1016/S2213-8587(21)00265-5

No abstract available

PubMed Disclaimer

Conflict of interest statement

I disclose research grants or other support related to diabetes and chronic kidney disease from Eli Lilly, Boehringer Ingelheim, Bayer, Gilead, Astra Zeneca, Goldfinch Bio, Novo Nordisk, and Travere.

Comment on

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Jongs N, et al. Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4. Lancet Diabetes Endocrinol. 2021. PMID: 34619106 Clinical Trial.
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Greene T; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4. Lancet Diabetes Endocrinol. 2021. PMID: 34619108 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial

Affiliation

Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial

Author

Affiliation

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous